# A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

> **NCT01328626** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 222 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** ABT-199

## Key facts

- **NCT ID:** NCT01328626
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-23
- **Primary completion:** 2020-05-08
- **Final completion:** 2020-05-08
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2022-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328626, "A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01328626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*